Alterola Biotech, Inc. (OTCMKTS:ALTA) Files An 8-K Changes in Registrant’s Certifying Accountant

ME Staff 8-k
-
0
Alterola Biotech, Inc. (OTCMKTS:ALTA) Files An 8-K Changes in Registrant’s Certifying Accountant

Alterola Biotech, Inc. (OTCMKTS:ALTA) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01 Changes in Registrant’s Certifying Accountant.

On May 31, 2019, MJF & Associates (the “Former Accountant”) resigned as the Company’s independent registered public accounting firm.

The Former Accountant’s audit report on the financial statements of the Company for the fiscal years ended September 30, 2017 and 2016 contained no adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles, except that the audit reports on the financial statements of the Company for the fiscal years ended September 30, 2017 and 2016 contained an uncertainty about the Company’s ability to continue as a going concern.

During the fiscal years ended September 30, 2017 and 2016, and through the interim period ended May 31, 2019, there were no “disagreements” (as such term is defined in Item 304 of Regulation S-K) with the Former Accountant on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to the satisfaction of the Former Accountant would have caused them to make reference thereto in their reports on the financial statements for such periods.

During the fiscal years ended September 30, 2017 and 2016, and through the interim period ended May 31, 2019, there were the following “reportable events” (as such term is defined in Item 304 of Regulation S-K). As disclosed in Part I, Item 4 of the Company’s Form 10-Q for the quarter ended March 31, 2018, the Company’s management determined that the Company’s internal controls over financial reporting were not effective as of the end of such period due to the existence of material weaknesses related to the following:

SECTION 9 – Financial Statements and ExhibiTS

Item 9.01 Financial Statements and Exhibits.


ALTEROLA BIOTECH INC. Exhibit
EX-16.1 2 ex16_1.htm         June 19,…
To view the full exhibit click here

About Alterola Biotech, Inc. (OTCMKTS:ALTA)

Alterola Biotech, Inc. is a development-stage company. The Company is focused on nutrition and health chewing gum with natural-based ingredients. It intends to expand its product line with gums having medical effects, such as painkillers and antihistamine medications with gum delivery. The Company’s products under development include Appetite suppressor, Cholesterol suppressor, Antioxidant gum, Motion sickness suppressor and Vitamin gum. Appetite suppressor is a chewing gum containing an extract of Hoodia gordonii and 2-hydroxyoleic acid, and is directed to treatment of obesity, hypertension and metabolic disorders. Cholesterol suppressor consists of Curcumin, the dietary polyphenol isolated from turmeric, which can inhibit cholesterol uptake in the enterocytes. It also focuses on pharmaceutical chewing gum, such as Painkiller and Anti-Histamine. As of March 31, 2016, the Company had not generated any revenues.